News
Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly improved” as compared to placebo—the second positive readout for the asset this week.
FEATURED STORIES
While the pathogen appears unlikely to trigger a pandemic, analysts see potential for Moderna to build goodwill amid a period of political pressure on vaccine manufacturers.
Clinical trial setbacks have limited the near-term opportunities for some of Daiichi Sankyo’s ADCs but the drug developer is betting near-term readouts will catapult it into the top tier of oncology companies in the coming years.
BioSpace analyzed the pay ratio across 10 major pharmaceutical companies to determine which CEOs were paid the most relative to typical employees. J&J, Eli Lilly and Pfizer once again topped the list.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
The Department of Health and Human Services is spinning its wheels, unable to establish steady leadership at three major divisions—the CDC and the FDA’s two primary review units.
THE LATEST
Eli Lilly’s Jardiance scores expanded heart failure approval from the FDA and will now be available to all patients with heart failure to reduce the risk of death and hospitalization.
The FDA’s decision to approve Purdue’s drug Nalmefene earned mixed reactions, especially as the company is in the middle of lawsuits. Here’s what you need to know.
Studies from Guttmacher Institute found that 54% of all abortions in the United States in 2020 were done with pills instead of surgery, an increase from approximately 44% in 2019.
The agreement would have created a spin-off gene therapy company and merged it with ARYA IV to create a new, publicly-traded entity called Caritas Therapies.
Not only is this the first approval for a plant-based vaccine, it’s also the first approval for GSK’s adjuvant.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
After Judge Denise Cotes banned Martin Shkreli from future involvement in the industry, a second judge handed down a similar order and ordered him to pay a $1.39 million fine.
Moderna, Pfizer and BioNTech and Johnson & Johnson earned an approximate combined revenue of $31 billion in 2021, thanks to the success of their mRNA vaccines against COVID-19.
The new normal may not be particularly new. Although cases appear to be dropping — deaths in the unvaccinated are still high. For that and more COVID-19 stories, continue reading.
Biopharma companies are continuously working to test new treatments to the market. Here are three clinical updates announced this week, spanning three different continents.